Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
Purpose. To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injec...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2012/861384 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563752909668352 |
|---|---|
| author | Leila El Matri Rym Bouraoui Ahmed Chebil Fedra Kort Mejda Bouladi Rym Limaiem Hana Landoulsi |
| author_facet | Leila El Matri Rym Bouraoui Ahmed Chebil Fedra Kort Mejda Bouladi Rym Limaiem Hana Landoulsi |
| author_sort | Leila El Matri |
| collection | DOAJ |
| description | Purpose. To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injection. Results. Mean followup was 14.1 months ±7.1 (range: 5 to 24 months). Mean logMAR vision at baseline was 1.38 logMAR ±0.33, at 6 months was 1.14 logMAR ±0.37 (𝑃=0.001) and at 12 months was 1.22 logMar ±0.33 (𝑃=0.004). Mean baseline central retinal thickness was 431 μm ±159.7 at 6 months was 293.43 μm ±122.79 (𝑃=10−4) and at 12 months was 293.1 μm ±130 (𝑃=0.004). Visual acuity improved in both patients with or without prior PDT treatment. Conclusions. Intravitreal bevacizumab injection may increase the chance of visual acuity gain in neovascular AMD even in cases with initial low visual acuity. |
| format | Article |
| id | doaj-art-0d2f8bfca86d4ae18dc3ddf1288ee636 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-0d2f8bfca86d4ae18dc3ddf1288ee6362025-02-03T01:12:34ZengWileyJournal of Ophthalmology2090-004X2090-00582012-01-01201210.1155/2012/861384861384Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual AcuityLeila El Matri0Rym Bouraoui1Ahmed Chebil2Fedra Kort3Mejda Bouladi4Rym Limaiem5Hana Landoulsi6Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril, Bab Saadoun Tunis 1006, TunisiaDepartment B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril, Bab Saadoun Tunis 1006, TunisiaDepartment B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril, Bab Saadoun Tunis 1006, TunisiaDepartment B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril, Bab Saadoun Tunis 1006, TunisiaDepartment B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril, Bab Saadoun Tunis 1006, TunisiaDepartment B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril, Bab Saadoun Tunis 1006, TunisiaDepartment B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril, Bab Saadoun Tunis 1006, TunisiaPurpose. To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injection. Results. Mean followup was 14.1 months ±7.1 (range: 5 to 24 months). Mean logMAR vision at baseline was 1.38 logMAR ±0.33, at 6 months was 1.14 logMAR ±0.37 (𝑃=0.001) and at 12 months was 1.22 logMar ±0.33 (𝑃=0.004). Mean baseline central retinal thickness was 431 μm ±159.7 at 6 months was 293.43 μm ±122.79 (𝑃=10−4) and at 12 months was 293.1 μm ±130 (𝑃=0.004). Visual acuity improved in both patients with or without prior PDT treatment. Conclusions. Intravitreal bevacizumab injection may increase the chance of visual acuity gain in neovascular AMD even in cases with initial low visual acuity.http://dx.doi.org/10.1155/2012/861384 |
| spellingShingle | Leila El Matri Rym Bouraoui Ahmed Chebil Fedra Kort Mejda Bouladi Rym Limaiem Hana Landoulsi Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity Journal of Ophthalmology |
| title | Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity |
| title_full | Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity |
| title_fullStr | Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity |
| title_full_unstemmed | Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity |
| title_short | Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity |
| title_sort | bevacizumab injection in patients with age related macular degeneration associated with poor initial visual acuity |
| url | http://dx.doi.org/10.1155/2012/861384 |
| work_keys_str_mv | AT leilaelmatri bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity AT rymbouraoui bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity AT ahmedchebil bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity AT fedrakort bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity AT mejdabouladi bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity AT rymlimaiem bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity AT hanalandoulsi bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity |